Syntex (u.s.a.) Inc.

Hoffmann-la Roche Inc.

Paula Nanette Belloni

Michael J Klaus

Jean-Marc Lapierre

Gary A Peltz

John O Link

Peter Mohr

Synese Jolidon

Dror Harats

Denis John Kertesz

John J Nestor, Jr

Donald Roy Hirschfeld

Hiroki Kurihara

Charles Elliott Sigal

The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.

Alkyl urea retinoid agonists

Selective retinoid agonists

Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid

New compounds containing bicyclic fused rings, one of which being a phenyl moiety connected by an aliphatic chain to a cycloalkyl or aryl moiety, and pharmaceutically active salts thereof are useful as RAR selective retinoid agonists. Furthermore, such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, are useful for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumors and precancerous changes of the mucous membrane in the mouth, tongue, larynx, esophagus, bladder, cervix and colon.

RAR selective retinoid agonists

Selective retinoid acid receptor agonists

Methods for treatment of Emphysema using 13-cis retinoic acid

This invention provides methods of treating emphysema and other diseases associated with alveolar damage by treatment with an RAR&ggr; selective agonist. In another aspect, this invention provides methods of promoting tropoelastin gene expression and alveolar matrix repair by contacting the pulmonary intestitial fibroblast with an RAR agonist, preferably an RAR&ggr; selective agonist.

Treatment of emphysema using RARy selective retinoid agonists

Truncated forms of inhibitory kappa B protein (I&kgr;B-&agr;), nucleic acids encoding the truncates, expression and delivery vectors, and therapeutic and prophylatic uses thereof are provided.

Nucleic acids encoding truncated forms of inhibitory kappa B protein

This invention provides methods of of inhibiting mucin production in a mammal comprising administering to the mammal an RAR antagonist. Preferably, the RAR antagonist is an RAR.alpha. selective antagonist. In another aspect, this invention provides methods of inhibiting mucin gene expression in a human epithelial cell by contacting the cell with an RAR antagonist, preferably an RAR.alpha. selective antagonist.

Methods for inhibiting mucin secretion using RAR .alpha. selective

This invention provides novel cationic lipids, particularly guanidino lipids, and methods for their preparation. Also provided are polyanionic-lipid complexes comprising the lipids of the invention, their preparation and use to deliver biologically active substances, particularly nucleic acids to cells.

Cationic lipids for gene therapy

This invention provides a vector for expression of a nucleic acid cassette in bronchial epithelial and vascular endothelial cells comprising a segment of the 5'-flanking region of the preproendothelin-1 gene, upstream from the transcription start site, the first exon of the preproendothelin-1 gene, and a nucleic acid cassette, wherein the nucleic acid cassette is located within the first exon, in sequential and positional relationship for expression of the nucleic acid cassette.

Growing community of inventors

Half Moon Bay, CA, United States of America

Paula Nanette Belloni